Literature DB >> 6201140

Tyrosinase activity and abundance in Cloudman melanoma cells.

R Halaban, S H Pomerantz, S Marshall, A B Lerner.   

Abstract

Rabbit anti-tyrosinase antibodies were used to study the abundance, processing, and degradation of tyrosinase in murine (Cloudman) melanoma cells. The polyclonal antibodies precipitated low-molecular-weight (68,000 and 70,000) and high-molecular-weight (78,000 and 80,000) tyrosinases that had a precursor-product relationship. Cells with high basal tyrosinase activity had high levels of newly synthesized tyrosinase. Cells with low tyrosinase activity synthesized less tyrosinase and degraded the enzyme at a faster rate than cells with high tyrosinase activity. Melanotropin (melanocyte stimulating hormone), dibutyryl cyclic adenosine monophosphate, and isobutylmethylxanthine caused an increase in the abundance of newly synthesized tyrosinase that was directly proportional to the increase in enzyme activity. This enzyme was not a phosphoprotein. Other changes in the culture conditions that increased the level of tyrosinase activity increased the abundance of newly synthesized enzyme. It is thus concluded that the level of tyrosinase activity in Cloudman melanoma cells is a direct reflection of the abundance of enzyme protein.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201140     DOI: 10.1016/0003-9861(84)90121-8

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  17 in total

1.  MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes.

Authors:  Hee-Young Park; Christina Wu; Laurie Yonemoto; Melissa Murphy-Smith; Heng Wu; Christina M Stachur; Barbara A Gilchrest
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

2.  A frequent tyrosinase gene mutation in classic, tyrosinase-negative (type IA) oculocutaneous albinism.

Authors:  L B Giebel; K M Strunk; R A King; J M Hanifin; R A Spritz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism.

Authors:  R Halaban; S Svedine; E Cheng; Y Smicun; R Aron; D N Hebert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells.

Authors:  Konrad Kleszczyński; Tae-Kang Kim; Bernadetta Bilska; Michal Sarna; Krystian Mokrzynski; Agatha Stegemann; Elżbieta Pyza; Russel J Reiter; Kerstin Steinbrink; Markus Böhm; Andrzej T Slominski
Journal:  J Pineal Res       Date:  2019-10-07       Impact factor: 13.007

5.  Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family.

Authors:  D Jean; M Bar-Eli
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 6.  Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Authors:  Russell R Braeuer; Maya Zigler; Gabriel J Villares; Andrey S Dobroff; Menashe Bar-Eli
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

Review 7.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

8.  Mammalian tyrosinase: biosynthesis, processing, and modulation by melanocyte-stimulating hormone.

Authors:  M Jiménez; K Kameyama; W L Maloy; Y Tomita; V J Hearing
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Activation of tyrosinase in mouse melanoma cell cultures.

Authors:  B B Fuller
Journal:  In Vitro Cell Dev Biol       Date:  1987-09

10.  Tyrosinases of murine melanocytes with mutations at the albino locus.

Authors:  R Halaban; G Moellmann; A Tamura; B S Kwon; E Kuklinska; S H Pomerantz; A B Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.